Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TLC599 in Osteoarthritis of the Knee
NCT04123561Phase 3Completed
- Sponsor
- Taiwan Liposome Company
- Start
- Nov 2019
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of TLC599 in knee osteoarthritis (OA) (3 arms), sponsored by Taiwan Liposome Company. Primary endpoint: Change From Baseline in WOMAC Pain at 12 weeks. Started Nov 2019; status: completed.
02
Drugs
TLC599
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT04123561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04123561.